Literature DB >> 6602172

Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b.

J L Meuth, E L Morgan, R G DiSipio, T E Hugli.   

Abstract

Cleavage of human iC3b by kallikrein isolated from human plasma generates a fragment, C3d-K, which is capable of inhibiting mitogen-, antigen-, and alloantigen-induced T lymphocyte proliferation. Native C3, C3a, C3b, and C3c-K had no effect on lymphocyte proliferative responses. In addition to being a potent suppressor of mitogen- and antigen-induced proliferation, C3d-K is capable of inducing leukocytosis in both mice and rabbits. Intravenous injection of C3d-K, but not C3, C3a, C3b, or C3c-K, results in a twofold to threefold increase in the number of circulating leukocytes. Thus, C3d-K exhibits two apparently independent functions, namely suppression of T cell proliferation and leukocytosis. Cleavage of iC3b by kallikrein results in the production of only two fragments. The larger fragment, C3c-K, is 144,000 m.w. and has a chemical structure analogous to that of C3c obtained from the cleavage of C3 by trypsin or elastase. The smaller fragment, C3d-K, is 41,000 m.w. and contains the metastable binding site of C3. It is through this site located in the C3d region of the molecule that C3 attaches covalently to target cells. Analysis of the amino terminal region of C3d-K provided a sequence that fails to overlap with any sequence yet reported for other characterized C3 fragments, including C3d originally obtained from elastase digestion. A revised model of the C3 molecule is proposed, with locations of the C3e and C3d fragments assigned on the basis of chemical analyses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602172

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.

Authors:  J D Lambris; V S Ganu; S Hirani; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

2.  Covalent binding of C3b to tetanus toxin: influence on uptake/internalization of antigen by antigen-specific and non-specific B cells.

Authors:  M B Villiers; C L Villiers; M R Jacquier-Sarlin; F M Gabert; A M Journet; M G Colomb
Journal:  Immunology       Date:  1996-11       Impact factor: 7.397

3.  Human complement component C3: cDNA coding sequence and derived primary structure.

Authors:  M H de Bruijn; G H Fey
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

4.  Generation of complement C3 and expression of cell membrane complement inhibitory proteins by human bronchial epithelium cell line.

Authors:  S Varsano; M Kaminsky; M Kaiser; L Rashkovsky
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

5.  The third component of complement is transcribed and secreted by cultured human endothelial cells.

Authors:  H B Warren; P Pantazis; P F Davies
Journal:  Am J Pathol       Date:  1987-10       Impact factor: 4.307

6.  Complement subcomponent C1q secreted by cultured human monocytes has subunit structure identical with that of serum C1q.

Authors:  A J Tenner; D B Volkin
Journal:  Biochem J       Date:  1986-01-15       Impact factor: 3.857

7.  Generation of the bioactive kallikrein-derived fragment, C3d-k, by HANE-plasma.

Authors:  T Seya; S Nagasawa; J P Atkinson
Journal:  Clin Exp Immunol       Date:  1985-10       Impact factor: 4.330

Review 8.  The chemistry and biology of complement receptors.

Authors:  R D Schreiber
Journal:  Springer Semin Immunopathol       Date:  1984

9.  Domain structure of bi-functional selenoprotein P.

Authors:  Yoshiro Saito; Noriko Sato; Masaki Hirashima; Gen Takebe; Shigeharu Nagasawa; Kazuhiko Takahashi
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

10.  Plasminogen activation in plasma of patients with systemic lupus erythematosus.

Authors:  N Negoro; Y Kanayama; T Takeda; M Fujisawa; M Okamura; T Inoue
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.